Please find enclosed News release of our company

Suven Life Sciences will participate in the BIO International Convention 2026 in San Diego to showcase its differentiated Central Nervous System (CNS) clinical candidates, including late-stage assets for Alzheimer's agitation, major depressive disorder, and narcolepsy. The company aims to engage with global pharmaceutical and biotechnology firms through 62 pre-scheduled meetings to explore partnering strategies, out-licensing, and co-development initiatives for its pipeline. This move seeks to accelerate the development and commercialization of its innovative treatments.